Transcriptional Factor Specificity Protein 1 (SP1) Promotes the Proliferation of Glioma Cells by Up-regulating Midkine (MDK)

Overview

Journal Mol Biol Cell

Specialties Cell Biology
Molecular Biology

Date 2014 Nov 28

PMID 25428991

Citations 37

Authors

Jingyan Luo

Xiaoxiao Wang

Zhibo Xia

Lixuan Yang

Zhiming Ding

Shiyuan Chen

Bingquan Lai

Nu Zhang

Affiliations

Soon will be listed here.

Abstract

Midkine (MDK) expression is associated with the proliferation of many cancers, including glioma. However, the upstream signaling that leads to MDK accumulation remains elusive. This study investigates the molecular mechanism that induces MDK overexpression in human glioma. The Repository for Molecular Brain Neoplasia Data was analyzed to identify potential MDK regulators. Expression of MDK and specificity protein 1 (SP1) was compared in glioma specimens. Chromatin immunoprecipitation assay was used to confirm the transcriptional regulation. MDK-force-expressed, SP1-silenced glioma cells were used to test rescue effects in vitro and in vivo. MDK and SP1 expression in gliomas was significantly higher than in adjacent tissues and was positively correlated in glioma clinical samples and cell lines. The promoter of the human MDK gene has a putative SP1 binding site. SP1 binds to the promoter of the MDK gene and directly regulates MDK expression. MDK or SP1 gene silencing inhibited the proliferation of glioma cells and reduced the tumor volume in nude mice. Overexpression of MDK in SP1-silenced cells could partially rescue the SP1 inhibition effects in vivo and in vitro. SP1 directly up-regulated the expression of MDK, and the SP1-MDK axis cooperated in glioma tumorigenesis.

Citing Articles

Multi-scale signaling and tumor evolution in high-grade gliomas.

Liu J, Cao S, Imbach K, Gritsenko M, Lih T, Kyle J Cancer Cell. 2024; 42(7):1217-1238.e19.

PMID: 38981438 PMC: 11337243. DOI: 10.1016/j.ccell.2024.06.004.

C-Myc/H19/miR-29b axis downregulates nerve/glial (NG)2 expression in glioblastoma multiforme.

Boewe A, Wrublewsky S, Hoppstadter J, Gotz C, Kiemer A, Menger M Mol Ther Nucleic Acids. 2024; 35(1):102120.

PMID: 38318212 PMC: 10839451. DOI: 10.1016/j.omtn.2024.102120.

Identification of as a Hypoxia- and Epithelial-Mesenchymal Transition-Related Gene Biomarker of Glioblastoma Based on a Novel Risk Model and In Vitro Experiments.

Xia M, Tong S, Gao L Biomedicines. 2024; 12(1).

PMID: 38255198 PMC: 10813330. DOI: 10.3390/biomedicines12010092.

Sp1 Upregulation Bolsters the Radioresistance of Glioblastoma Cells by Promoting Double Strand Breaks Repair.

Liu X, Sun C, Wang Q, Li P, Zhao T, Li Q Int J Mol Sci. 2023; 24(13).

PMID: 37445835 PMC: 10342049. DOI: 10.3390/ijms241310658.

Role of Midkine in Cancer Drug Resistance: Regulators of Its Expression and Its Molecular Targeting.

Saikia M, Cheung N, Singh A, Kapoor V Int J Mol Sci. 2023; 24(10).

PMID: 37240085 PMC: 10218550. DOI: 10.3390/ijms24108739.

References

Ma Z, Li H, Wang B, Shen Q, Cui E, Min L . Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study. J Cancer Res Clin Oncol. 2012; 139(4):557-62. DOI: 10.1007/s00432-012-1357-1. View

Hsu T, Wang M, Chen S, Yeh Y, Su W, Chang W . Sp1 expression regulates lung tumor progression. Oncogene. 2011; 31(35):3973-88. PMC: 3432230. DOI: 10.1038/onc.2011.568. View

Ishibashi H, Nakagawa K, Onimaru M, Castellanous E, Kaneda Y, Nakashima Y . Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. Cancer Res. 2000; 60(22):6531-6. View

Kriwacki R, SCHULTZ S, Steitz T, Caradonna J . Sequence-specific recognition of DNA by zinc-finger peptides derived from the transcription factor Sp1. Proc Natl Acad Sci U S A. 1992; 89(20):9759-63. PMC: 50212. DOI: 10.1073/pnas.89.20.9759. View

Nobata S, Shinozawa T, Sakanishi A . Truncated midkine induces transformation of cultured cells and short latency of tumorigenesis in nude mice. Cancer Lett. 2005; 219(1):83-9. DOI: 10.1016/j.canlet.2004.07.003. View

Bernsen H, Rijken P, Hagemeier N, van der Kogel A . A quantitative analysis of vascularization and perfusion of human glioma xenografts at different implantation sites. Microvasc Res. 1999; 57(3):244-57. DOI: 10.1006/mvre.1999.2143. View

Li L, Davie J . The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat. 2010; 192(5):275-83. DOI: 10.1016/j.aanat.2010.07.010. View

Lorente M, Torres S, Salazar M, Carracedo A, Hernandez-Tiedra S, Rodriguez-Fornes F . Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action. Cell Death Differ. 2011; 18(6):959-73. PMC: 3131933. DOI: 10.1038/cdd.2010.170. View

Zhu C, Lv Y, Yan D, Gao F . Knockdown of MDR1 increases the sensitivity to adriamycin in drug resistant gastric cancer cells. Asian Pac J Cancer Prev. 2014; 14(11):6757-60. DOI: 10.7314/apjcp.2013.14.11.6757. View

10.

Gopisetty G, Xu J, Sampath D, Colman H, Puduvalli V . Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation. Oncogene. 2012; 32(26):3119-29. PMC: 3820114. DOI: 10.1038/onc.2012.331. View

11.

Nagane M, Huang H, Cavenee W . Advances in the molecular genetics of gliomas. Curr Opin Oncol. 1997; 9(3):215-22. DOI: 10.1097/00001622-199709030-00001. View

12.

Kishida S, Kadomatsu K . Involvement of midkine in neuroblastoma tumourigenesis. Br J Pharmacol. 2013; 171(4):896-904. PMC: 3925028. DOI: 10.1111/bph.12442. View

13.

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

14.

Miyashiro I, Kaname T, Shin E, Wakasugi E, Monden T, Takatsuka Y . Midkine expression in human breast cancers: expression of truncated form. Breast Cancer Res Treat. 1997; 43(1):1-6. DOI: 10.1023/a:1005748728351. View

15.

Ohuchida T, Okamoto K, Akahane K, Higure A, Todoroki H, Abe Y . Midkine protects hepatocellular carcinoma cells against TRAIL-mediated apoptosis through down-regulation of caspase-3 activity. Cancer. 2004; 100(11):2430-6. DOI: 10.1002/cncr.20266. View

16.

Wen P, Kesari S . Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507. DOI: 10.1056/NEJMra0708126. View

17.

Owada K, Sanjo N, Kobayashi T, Mizusawa H, Muramatsu H, Muramatsu T . Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem. 1999; 73(5):2084-92. View

18.

Tong Y, Mentlein R, Buhl R, Hugo H, Krause J, Mehdorn H . Overexpression of midkine contributes to anti-apoptotic effects in human meningiomas. J Neurochem. 2006; 100(4):1097-107. DOI: 10.1111/j.1471-4159.2006.04276.x. View

19.

Black A, Black J, Azizkhan-Clifford J . Sp1 and krüppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol. 2001; 188(2):143-60. DOI: 10.1002/jcp.1111. View

20.

Seznec J, Silkenstedt B, Naumann U . Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma. J Neurooncol. 2010; 101(3):365-77. DOI: 10.1007/s11060-010-0266-x. View